Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Summary of COVID-19 vaccine AEFI reports received in Saskatchewan

As of October 5, 2024, 1,407 reportable AEFI reports have been received following 3,106,210 doses of COVID-19 vaccines administered in SK with a reporting rate of 0.45 AEFIs per 1000 doses administered (0.045% of all doses administered). Refer to Tables 1 and 2 for more details.

 

AEFI Reports are updated every four weeks.

Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of October 5, 2024

  Pfizer
XBB.1.5
12y+
Pfizer
XBB.1.5
5-11y
Pfizer
XBB.1.5
6m-4y
Pfizer
BA.1
Pfizer
BA.4/5
12y+
Pfizer
BA.4/5
5-11y
Pfizer
Original
12y+
Pfizer
Original
5-11y
Pfizer
Original
6m-4y
Moderna
XBB.1.5
6m+
Moderna
BA.1
18y+
Moderna
BA.4/5
18y+<
Moderna
Original
6y+
Moderna
Original
6m-5y
Novavax XBB Novavax 12+ Astra
Zeneca 18+
COVI-
SHIELD
18+
Janssen
18+
Totals
Total number of doses administered 96,931 2,349 1,393 77 137,989 2,095 1,844,164 124,816 7,034 144,390 98,701 8,712 529,429 12,867 54 531 75,408 17,197 2,072 3,106,210
Total number of AEFI reports received 8 0 1 0 19 0 863 15 5 8 9 0 330 6 0 1 113 25 4 1,407
Number of non-serious reports 8 0 1 0 17 0 798 14 5 8 8 0 316 6 0 1 95 24 3 1,304
Number of serious reports1 0 0 0 0 2 0 65 1 0 0 1 0 14 0 0 0 18 1 1 103
Proportion of serious AEFI reports 0% 0% 0% 0% 10.5% 0% 7.5% 6.7% 0% 0% 11.1% 0% 4.2% 0% 0% 0% 15.9% 4% 25% 7.3%
Total AEFI reporting rate per 1,000 doses administered 0.08 0 0.72 0 0.14 0 0.47 0.12 0.71 0.06 0.09 0 0.62 0.47 0 1.88 1.5 1.45 1.93 0.45
Serious AEFI reporting rate per 1,000 doses administered 0 0 0 0 0.01 0 0.04 0.01 0 0 0.01 0 0.03 0 0 0 0.24 0.06 0.48 0.03

1Serious criteria includes an adverse event that is life threatening or results in death, requires hospitalization or prolongation of an existing hospitalization, results in residual disability or causes congenital malformation.

Table 2: Cumulative Frequency of AEFIs Reported

Adverse event type # of events
Edema (allergic, not injection site) 313
Rashes (all) 271
Anesthesia/paresthesia 228
Injection site reactions 203
Gastrointestinal 151
Anaphylaxis 84
Chest tightness 73
Headache 69
Arthralgia/arthritis/joint pain 51
Malaise/lethargy 48
Fever 42
Not inclusive of all AEFIs that can be reported

There are safety signals identified by the Public Health Agency of Canada (PHAC) for vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), myocarditis/pericarditis, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) requiring provinces and territories to report these events as adverse events of special interest to the PHAC. As of October 5, 2024, 3 TTS, 36 myocarditis/pericarditis, 4 GBS and 0 CLS cases have been reported in Saskatchewan.

Information on reported adverse events following COVID-19 vaccination in Canada can be found at the PHAC AEFI reporting site at COVID-19 vaccine safety: Weekly report on side effects following immunization on Canada.ca.

We need your feedback to improve saskatchewan.ca. Help us improve